<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647579</url>
  </required_header>
  <id_info>
    <org_study_id>17100208</org_study_id>
    <nct_id>NCT03647579</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy</brief_title>
  <official_title>Effect of Single Dose Dexmedetomidine Versus Midazolam on Emergence Agitation and Recovery Profile When Added to Ketamine for Procedural Sedation and Analgesia in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Group I :The patients will receive midazolam intravenously (i.v.) in a dose of 0.05 mg/kg
      diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv).

      Group II : The patients will receive Dexmedetomidine intravenously (i.v.) in a dose of
      2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv).

      The objective of this study to evaluate the clinical effects, adverse effects and recovery
      time of two different sedative agents (midazolam and Dexmedetomidine) combined with ketamine
      during conscious sedation for child patient with haematological cancer undergoing BMA
      &amp;biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">April 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of drug mixture on procedural sedation and analgesia: Ramsay sedation score</measure>
    <time_frame>within the time of the procedure of bone marrow aspirate and biopsy</time_frame>
    <description>to assess efficacy of procedural sedation and analgesia with drug mixture;using Ramsay sedation score.
Ramsay score
Nervous, agitated, and/or restless.
Cooperative, orientated, quite patient.
Only obeying orders.
Sleeping, hitting the glabella, and responding to high voice suddenly
Sleeping, hitting the glabella, and responding to high voice slowly
No response to any of these stimulations Dexemeditomidine and midazolam will be started 2 minutes before procedure through a peripheral venous cannula and continued as maintainance, then ketamine will be administered over 10-20 s aiming to achieve a sedation level of 3 or 4 on Ramsay scale to start the procedure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Procedural Sedation and Analgesia During Bone Marrow Aspiration and Biopsy</condition>
  <arm_group>
    <arm_group_label>midazolam plus ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine plus ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine</intervention_name>
    <description>midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine</description>
    <arm_group_label>midazolam plus ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine</intervention_name>
    <description>Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine</description>
    <arm_group_label>dexmedetomidine plus ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All consecutive children with acute lymphoblastic leukemia undergoing bone marrow
             aspiration and biopsy.

        Exclusion criteria:

          -  previous sensitization or anaphylactic reaction to Dexmedetomidine, ketamine,and
             midazolam;

          -  evidence of head injury,

          -  raised intracranial or intraocular tension;

          -  use of drugs known to interact with either study agent;

          -  an American Society of Anesthesiologists (ASA) physical status score greater than 2.

          -  Also Patients with cardiovascular, respiratory, hepatic diseases and epilepsy will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Egypt Cancer Institute, Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed H Othman</investigator_full_name>
    <investigator_title>Assisstant professor of Anesthesia ICU and pain Relief</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

